Your browser doesn't support javascript.
loading
Treatment Effects in Retinal Angiomatous Proliferation Imaged with OCT Angiography.
de Jong, Jan H; Braaf, Boy; Amarakoon, Sankha; Gräfe, Maximilian; Yzer, Suzanne; Vermeer, Koenraad A; Missotten, Tom; de Boer, Johannes F; van Velthoven, Mirjam E J.
Afiliación
  • de Jong JH; Rotterdam Ophthalmic Institute, Rotterdam, The Netherlands.
  • Braaf B; Rotterdam Eye Hospital, Rotterdam, The Netherlands.
  • Amarakoon S; Institute for Lasers, Life and Biophotonics Amsterdam, Department of Physics and Astronomy, VU University, Amsterdam, The Netherlands.
  • Gräfe M; Rotterdam Ophthalmic Institute, Rotterdam, The Netherlands.
  • Yzer S; Rotterdam Eye Hospital, Rotterdam, The Netherlands.
  • Vermeer KA; Institute for Lasers, Life and Biophotonics Amsterdam, Department of Physics and Astronomy, VU University, Amsterdam, The Netherlands.
  • Missotten T; Rotterdam Ophthalmic Institute, Rotterdam, The Netherlands.
  • de Boer JF; Rotterdam Eye Hospital, Rotterdam, The Netherlands.
  • van Velthoven MEJ; Rotterdam Ophthalmic Institute, Rotterdam, The Netherlands.
Ophthalmologica ; 241(3): 143-153, 2019.
Article en En | MEDLINE | ID: mdl-30227415
ABSTRACT

PURPOSE:

This prospective case series is aimed at exploring optical coherence tomographic angiography (OCT-A) as a treatment monitoring tool in patients treated for retinal angiomatous proliferation (RAP).

METHODS:

Twelve treatment-naïve RAP patients were included, with a median age of 79 years (range 65-90). Patients were imaged with an experimental 1,040-nm swept-source phase-resolved OCT-A instrument before and after treatment. Treatment consisted of either intravitreal bevacizumab or triamcinolone injections with or without photodynamic therapy (PDT). Abnormal blood flow after treatment was graded as increased, unchanged, decreased, or resolved.

RESULTS:

OCT-A images before and after treatment could be obtained in 9 patients. The median follow-up period was 10 weeks (range 5-19). After various treatments, the RAP lesion resolved in 7 patients, in 1 patient the OCT-A depicted decreased flow in the lesion, and 1 patient showed unchanged abnormal blood flow. Monotherapy with intravitreal bevacizumab injections resolved RAP in 1 out of 2 patients. Combined therapy of bevacizumab with PDT resolved RAP in 6 out of 7 patients.

CONCLUSIONS:

OCT-A visualized resolution of abnormal blood flow in 7 out of 9 RAP patients after various short-term treatment sequences. OCT-A may become an important noninvasive monitoring tool for optimizing treatment strategies in RAP patients.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Fotoquimioterapia / Triamcinolona / Angiografía con Fluoresceína / Neovascularización Retiniana / Tomografía de Coherencia Óptica / Bevacizumab / Degeneración Macular Tipo de estudio: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Aged80 / Female / Humans / Male Idioma: En Revista: Ophthalmologica Año: 2019 Tipo del documento: Article País de afiliación: Países Bajos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Fotoquimioterapia / Triamcinolona / Angiografía con Fluoresceína / Neovascularización Retiniana / Tomografía de Coherencia Óptica / Bevacizumab / Degeneración Macular Tipo de estudio: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Aged80 / Female / Humans / Male Idioma: En Revista: Ophthalmologica Año: 2019 Tipo del documento: Article País de afiliación: Países Bajos